journal article·2026-05Open access

Nicotinamide and Pyridoxine Supplementation Enhances Muscle Stem Cell Activity and Muscle Regeneration in Humans: A Randomized Placebo‐Controlled Clinical Trial of High Force Eccentric Contraction Recovery in Healthy Young Men

Grith Højfeldt, Joris Michaud, Ann Damgaard, Karoline Karlog, Eugenia Migliavacca, Sonia Karaz, Elham Pazirandeh‐Micol, Odd E. Johansen, Leonidas G. Karagounis, Bjørk W. Helge, William Hagemann, Michael Kjaer, Jerome N. Feige, Pascal Stuelsatz, Abigail L. Mackey

Advanced Science· Volume 13· Issue 28

Abstract

ABSTRACT Muscle Stem Cells (MuSCs) drive muscle regeneration and slow pathological progression of muscle diseases. In preclinical models, nicotinamide (NAM) and pyridoxine (PN) synergistically increased MuSC proliferation and differentiation, and accelerated muscle regeneration. Herein we tested if NAM/PN could enhance MuSC activity and muscle regeneration in a randomized, placebo‐controlled clinical trial. Men aged 18–49 years were supplemented daily with 714 mg NAM and 19 mg PN, or placebo, for 9 days following one session of damaging unilateral eccentric muscle contractions. The primary endpoint was MuSC activity via immunohistofluorescence on biopsy sections from the vastus lateralis muscle. Histological markers of muscle regeneration constituted secondary outcomes, and muscle damage was validated with clinical markers. 39 out of 43 enrolled participants completed the study. Supplementation of NAM/PN was well tolerated and increased blood concentrations of NAM and PN vitamers. 8 days after the contraction protocol, the number of Pax7, MyoD, and myogenin positive cells per damaged fiber was significantly higher in NAM/PN vs placebo groups (+29%–67%). NAM/PN also increased the proportion of regenerating fibers (+37%). Daily oral NAM/PN supplementation after high intensity muscle contractions enhances MuSC activity and accelerates muscle regeneration and repair, providing new opportunities for therapeutic applications in muscle recovery and muscle wasting disorders.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Muscle Physiology and Disorders · Sirtuins and Resveratrol in Medicine · PARP inhibition in cancer therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Sports Medicine Copenhagen Department of Orthopaedic Surgery Copenhagen University Hospital – Bispebjerg and Frederiksberg Copenhagen Denmark

Department of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Denmark

Nestlé Institute of Health Sciences Nestlé Research Lausanne Switzerland

Clinical Research Unit Nestlé Research Lausanne Switzerland

Translational Research Nestlé Health Science Vevey Switzerland

Mary MacKillop Institute for Health Research (MMIHR) Australian Catholic University Melbourne Australia

Institute of Social and Preventive Medicine (ISPM) University of Bern Bern Switzerland

Funding

Novo Nordisk Fonden · Lundbeck Foundation · Nestlé Health Science

References (87)

Show source-provided references
1. 10.1002/j.2040‐4603.2015.tb00646.x10.1002/j.2040‐4603.2015.tb00646.x ↗
2. 10.1242/dev.16719710.1242/dev.167197 ↗
3. 10.1002/ar.2263110.1002/ar.22631 ↗
4. 10.1007/s11357‐013‐9583‐210.1007/s11357‐013‐9583‐2 ↗
5. 10.1038/ncomms808710.1038/ncomms8087 ↗
6. 10.1186/s13395‐015‐0067‐110.1186/s13395‐015‐0067‐1 ↗
7. 10.1152/ajpcell.00090.202010.1152/ajpcell.00090.2020 ↗
8. 10.1038/nm.371010.1038/nm.3710 ↗
9. 10.1007/s10974‐014‐9376‐y10.1007/s10974‐014‐9376‐y ↗
10. 10.1096/fj.202500177R10.1096/fj.202500177R ↗
11. 10.1186/s13395‐025‐00407‐010.1186/s13395‐025‐00407‐0 ↗
12. 10.3389/fphys.2015.0028310.3389/fphys.2015.00283 ↗
13. 10.1007/s00018‐019‐03093‐610.1007/s00018‐019‐03093‐6 ↗
14. 10.1096/fj.202101096R10.1096/fj.202101096R ↗
15. 10.5435/00124635‐200107000‐0000210.5435/00124635‐200107000‐00002 ↗
16. 10.1038/s41572‐023‐00469‐810.1038/s41572‐023‐00469‐8 ↗
17. 10.1113/JP28650710.1113/JP286507 ↗
18. 10.1186/s13395‐023‐00322‐210.1186/s13395‐023‐00322‐2 ↗
19. 10.1038/nrdp.2017.10510.1038/nrdp.2017.105 ↗
20. 10.1111/1440‐1681.1255910.1111/1440‐1681.12559 ↗
21. 10.1172/JCI6852310.1172/JCI68523 ↗
22. Impaired Regeneration in Dystrophic Muscle‐New Target for Therapy
23. 10.1038/s41467‐020‐20760‐610.1038/s41467‐020‐20760‐6 ↗
24. 10.1038/nm.391810.1038/nm.3918 ↗
25. 10.1096/fj.202000196R10.1096/fj.202000196R ↗
26. 10.1136/bjsports‐2011‐09029710.1136/bjsports‐2011‐090297 ↗
27. 10.1136/bjsports‐2019‐10125310.1136/bjsports‐2019‐101253 ↗
28. 10.1111/j.1600‐0838.2012.01463.x10.1111/j.1600‐0838.2012.01463.x ↗
29. 10.1096/fj.201500198R10.1096/fj.201500198R ↗
30. 10.1177/036354651769795710.1177/0363546517697957 ↗
31. 10.1172/JCI16364810.1172/JCI163648 ↗
32. 10.1371/journal.pone.014719810.1371/journal.pone.0147198 ↗
33. 10.1152/japplphysiol.00577.201610.1152/japplphysiol.00577.2016 ↗
34. 10.1113/JP27399710.1113/JP273997 ↗
35. 10.1186/s13395‐017‐0142‐x10.1186/s13395‐017‐0142‐x ↗
36. 10.1113/jphysiol.2007.12882710.1113/jphysiol.2007.128827 ↗
37. 10.1113/jphysiol.2004.06184610.1113/jphysiol.2004.061846 ↗
38. 10.1002/stem.128810.1002/stem.1288 ↗
39. 10.1016/j.exger.2022.11197410.1016/j.exger.2022.111974 ↗
40. 10.1016/j.stemcr.2024.05.00510.1016/j.stemcr.2024.05.005 ↗
41. 10.1083/jcb.20060812210.1083/jcb.200608122 ↗
42. 10.1093/stmcls/sxad09110.1093/stmcls/sxad091 ↗
43. 10.1186/s13395‐015‐0046‐610.1186/s13395‐015‐0046‐6 ↗
44. Hathcock J. N. · 2024
45. 10.1016/j.jada.2010.08.00610.1016/j.jada.2010.08.006 ↗
46. 10.1093/ajcn/87.5.144610.1093/ajcn/87.5.1446 ↗
47. 10.1093/advances/nmab03310.1093/advances/nmab033 ↗
48. 10.3390/metabo1207063010.3390/metabo12070630 ↗
49. 10.1016/j.cmet.2018.03.01810.1016/j.cmet.2018.03.018 ↗
50. 10.1172/jci.insight.15831410.1172/jci.insight.158314 ↗
51. 10.1126/sciadv.add516310.1126/sciadv.add5163 ↗
52. Silva V. R. · 2020 · 22510.1016/B978-0-323-66162-1.00013-5 ↗
53. 10.3390/ijms2003058710.3390/ijms20030587 ↗
54. 10.1071/AN1580710.1071/AN15807 ↗
55. 10.1002/jcp.3081210.1002/jcp.30812 ↗
56. 10.1210/jc.2006‐035710.1210/jc.2006‐0357 ↗
57. 10.1152/ajpendo.00502.200110.1152/ajpendo.00502.2001 ↗
58. 10.1136/bjsports‐2017‐09760810.1136/bjsports‐2017‐097608 ↗
59. 10.1123/ijsnem.2015‐010210.1123/ijsnem.2015‐0102 ↗
60. 10.1097/MCO.0b013e32831cef7510.1097/MCO.0b013e32831cef75 ↗
61. 10.3945/ajcn.112.05551710.3945/ajcn.112.055517 ↗
62. 10.1007/s00726‐014‐1810‐310.1007/s00726‐014‐1810‐3 ↗
63. 10.1113/jphysiol.2006.10735910.1113/jphysiol.2006.107359 ↗
64. 10.1126/science.abe562010.1126/science.abe5620 ↗
65. 10.1249/00005768‐199205000‐0000410.1249/00005768‐199205000‐00004 ↗
66. 10.3390/biom1404041510.3390/biom14040415 ↗
67. 10.1038/s41580‐021‐00421‐210.1038/s41580‐021‐00421‐2 ↗
68. 10.1016/j.mam.2016.02.00210.1016/j.mam.2016.02.002 ↗
69. 10.1113/JP28267710.1113/JP282677 ↗
70. 10.1113/jphysiol.2013.25712110.1113/jphysiol.2013.257121 ↗
71. 10.1038/nrclinonc.2012.20910.1038/nrclinonc.2012.209 ↗
72. 10.18632/aging.10100610.18632/aging.101006 ↗
73. 10.1038/s41467‐023‐37595‐610.1038/s41467‐023‐37595‐6 ↗
74. 10.3389/fphar.2021.66549310.3389/fphar.2021.665493 ↗
75. 10.1212/CON.000000000000079210.1212/CON.0000000000000792 ↗
76. 10.1016/j.yexcr.2021.11290610.1016/j.yexcr.2021.112906 ↗
77. 10.1016/j.cell.2010.11.03910.1016/j.cell.2010.11.039 ↗
78. 10.1038/npjregenmed.2016.610.1038/npjregenmed.2016.6 ↗
79. 10.3389/fphys.2023.118098010.3389/fphys.2023.1180980 ↗
80. 10.1016/j.cell.2015.10.04910.1016/j.cell.2015.10.049 ↗
81. 10.1038/ncomms774510.1038/ncomms7745 ↗
82. 10.1073/pnas.121576510910.1073/pnas.1215765109 ↗
83. 10.1038/s41536‐022‐00204‐z10.1038/s41536‐022‐00204‐z ↗
84. 10.1016/j.stem.2016.09.01010.1016/j.stem.2016.09.010 ↗
85. 10.1002/rcm.401310.1002/rcm.4013 ↗
86. 10.3109/0036551750909578710.3109/00365517509095787 ↗
87. 10.1186/s13395‐018‐0186‐610.1186/s13395‐018‐0186‐6 ↗